Thornburg Focus Growth R3 holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Thornburg Focus Growth Fund Class R3 THCRX
- NAV / 1-Day Return 34.83 / 0.00
- Total Assets 229.9M
-
Adj. Expense Ratio
1.370%
- Expense Ratio 1.460%
- Distribution Fee Level Above Average
- Share Class Type Retirement, Medium
- Category Mid-Cap Growth
- Investment Style Large Growth
- Min. Initial Investment 0
- Status Open
- TTM Yield 0.00
- Turnover 34%
USD | NAV as of Jun 13, 2026 | 1-Day Return as of Jun 13, 2026, 12:11 AM GMT+0
Morningstar’s Analysis THCRX
Will THCRX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the THCRX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of THCRX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 48.8
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Microsoft Corp | 8.94 | 20M | Technology |
Alphabet Inc Class A | 8.02 | 18M | Communication Services |
Broadcom Inc | 6.50 | 14M | Technology |
Thornburg Capital Management | 4.47 | 10M | — |
Meta Platforms Inc Class A | 4.37 | 10M | Communication Services |
Credo Technology Group Holding Ltd | 3.95 | 9M | Technology |
Mastercard Inc Class A | 3.58 | 8M | Financial Services |
Argan Inc | 3.21 | 7M | Industrials |
Vertiv Holdings Co Class A | 2.97 | 7M | Industrials |
Royalty Pharma PLC Class A | 2.76 | 6M | Healthcare |
United States